Omeros corporation to announce second quarter 2016 financial results
on august 9, 2016
Seattle--(business wire)--omeros corporation (nasdaq: omer), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2016 financial results for the period ended june 30, 2016, on tuesday, august 9, 2016, after the market closes. omeros management will host a conference call and webcast that day at 4:30 p.m. eastern time (1:30 p.m. pacific time) to discuss the financial results. conference call details to access the live conference call via phone, please dial 844-831-4029 from the united states and canada or 920-663-6278 internationally. the participant passcode is 60834344. please dial in approximately 10 minutes prior to the start of the call. a telephone replay will be available for one week following the call and may be accessed by dialing 855-859-2056 from the united states and canada or 404-537-3406 internationally. the replay passcode is 60834344. to access the live and subsequently archived webcast of the conference call, go to omeros’ website at www.omeros.com and go to “events” under the investors section of the website. please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. about omeros corporation omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. derived from its proprietary pharmacosurgery® platform, the company’s first drug product, omidria® (phenylephrine and ketorolac injection) 1%/0.3%, was broadly launched in the u.s. in april 2015 for use during cataract surgery or intraocular lens (iol) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. in the european union, the european commission has approved omidria for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction) and to reduce postoperative eye pain. omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies, complement-mediated glomerulopathies, huntington’s disease and cognitive impairment, addictive and compulsive disorders, and preventing problems associated with urologic surgical procedures. in addition, omeros has a proprietary gpcr platform, which is making available an unprecedented number of new gpcr drug targets and corresponding compounds to the pharmaceutical industry for drug development, and a platform used to generate antibodies.
OMER Ratings Summary
OMER Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission